Antiangiogenic for treating retinal blinding diseases

VIAN Therapeutics focuses on developing innovative therapies that leverage advanced biotechnological approaches to address unmet medical needs. The company is dedicated to creating targeted treatments that enhance patient outcomes, particularly in the fields of oncology and rare diseases. Their pipeline includes a range of product candidates that utilize proprietary platforms designed to optimize drug delivery and efficacy, ensuring that therapies are both effective and safe for patients.

The technologies employed by VIAN Therapeutics encompass a variety of cutting-edge methodologies, including gene editing and novel drug formulation techniques. These technologies aim to improve the precision of therapeutic interventions, allowing for tailored treatments that can adapt to individual patient profiles. By integrating these advanced scientific principles, VIAN Therapeutics is positioned to make significant advancements in the treatment landscape, ultimately striving to transform the way diseases are managed and treated.

United States

VIAN Therapeutics is a visionary virtual pharma startup at the forefront of combating microvascular retinal diseases. Focused on conditions like diabetic retinopathy and age-related macular degeneration, we're pioneering a novel solution: VIAN-c4551, a groundbreaking cyclic peptide drug delivered via convenient eyedrop administration. By swiftly stabilizing retinal blood vessels, our non-invasive approach aims to halt vision deterioration earlier than traditional methods (e.g., intraocular injections). With millions affected, VIAN Therapeutics aims to redefine ocular care, offering hope for clearer sight and a brighter future of retinal health.

VIAN Therapeutics

Company Details